Welcome to another edition of Pharma Delta's Weekly Roundup, where we bring you the most recent developments shaping the pharmaceutical landscape. From strategic acquisitions to groundbreaking innovations, the industry is buzzing with activity. Let's delve into the headlines that are making waves this week.
1. Novartis Forges Ahead with Acquisition of MorphoSys
Novartis announces plans to acquire MorphoSys, a biopharmaceutical company renowned for its innovative oncology medicines. This strategic move aims to bolster Novartis's leading pipeline in oncology, further solidifying its position in this critical therapeutic area. With the inclusion of promising assets like pelabresib and tulmimetostat, Novartis is poised for impactful advancements in cancer treatment.
Transaction to include pelabresib, a late-stage BET
inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage
investigational dual inhibitor of EZH2 and EZH1 for solid tumors or lymphomas
2. FDA Halts Gilead's Blood Cancer Therapy Trials
Gilead faces a setback as the FDA imposes a hold on trials
for its blood cancer therapy, magrolimab. The decision follows concerns over
increased patient mortality rates observed in certain studies. As Gilead
navigates this regulatory challenge, it underscores the importance of safety
evaluations in drug development and the company's commitment to ensuring
patient well-being.
The company will stop testing the drug, magrolimab, for all
blood cancers and will review its safety across other studies such as those in
patients with colon and breast cancers.
Gilead gained access to the drug through its $4.9 billion
purchase of Forty Seven Inc in 2020.
Shares of the company, which forecast 2024 sales below
estimates late Tuesday, were down 3.6 per cent in noon trading
The drug is an antibody treatment that blocks a type of
protein, called CD47, which helps damaged cells avoid destruction by the immune
system
3. Biocon Biologics Strikes Deal with Sandoz for Biosimilar Products
Biocon Biologics enters into a strategic agreement with Sandoz for the sale and distribution of two cancer treatment biosimilars, Trastuzumab and Bevacizumab, in Australia. This collaboration expands access to vital cancer medications and strengthens Biocon Biologics' presence in the global market. The partnership underscores the importance of biosimilars in improving healthcare affordability and accessibility.
4. IISER Bhopal Innovates Technology for Drug Development
Indian Institute of Science Education and Research Bhopal (IISER Bhopal) pioneers a technology named 'BHOPAL' for linking chemical tags to proteins, facilitating drug development processes. This breakthrough enables precise modifications to proteins without compromising their efficacy, opening new avenues for targeted therapies in diseases like Alzheimer's and Parkinson's.
Through this technology, necessary chemical moieties can be linked to specific sites of a protein without harming the protein's efficacy.
Elaborating on the objectives of this research, Dr Kalia said, "Proteins are cellular entities that play crucial roles in all cellular functions. Protein dysfunction results in major life-threatening diseases such as Alzheimer's disease, Parkinson's disease, etc. Hence, developing effective approaches to study proteins in cells is crucial for developing therapeutic approaches targeting them."
5. Amgen's Innovative Approach to Weight Loss
Amgen introduces maridebart cafraglutide, or MariTide, a
novel drug developed based on genetic population data linking GIP receptor
activity to weight reduction. By combining GIP receptor blockade with GLP-1
stimulation, Amgen aims to revolutionize weight loss strategies, offering new
hope for individuals struggling with obesity.
6. AstraZeneca's Profits Soar, Driven by
Oncology Division
AstraZeneca nearly doubles its profit, buoyed by robust
performance in its oncology division, despite a slowdown in COVID-19 medication
sales. This stellar financial performance underscores AstraZeneca's resilience
and commitment to advancing cancer treatments that make a meaningful impact on
patients' lives.
7. AstraZeneca Invests in Gene Therapy
Facility, Creating Jobs
AstraZeneca demonstrates its commitment to innovation and
job creation with a $300 million investment in a gene therapy facility in
Maryland. This strategic initiative underscores AstraZeneca's dedication to
advancing cutting-edge therapies while fostering economic growth and employment
opportunities in the region.
8. BridgeBio Sells Partial Rights to Dwarfism Drug
BridgeBio strikes a deal with Kyowa Kirin International
plc., selling partial rights to a dwarfism drug for $100 million in Japan. This
transaction highlights BridgeBio's strategic approach to portfolio optimization
and collaboration, maximizing the potential of its therapeutic assets while
expanding global access to innovative treatments.
9. Valneva Collaborates with Pfizer on Lyme
Disease Vaccine
Valneva announces plans to co-develop a Lyme disease vaccine with Pfizer, signaling a significant step forward in addressing this prevalent infectious disease. This collaboration leverages the strengths of both companies in vaccine development, with the shared goal of delivering effective protection against Lyme disease.
10. Akums Drugs Files for IPO, Eyes
Fundraising
Akums Drugs and Pharmaceuticals Ltd. takes steps towards an
initial public offering (IPO), aiming to raise funds for expansion and debt
repayment. This move reflects Akums' growth ambitions and investor confidence
in its strategic vision. As Akums ventures into the public markets, it seeks to
capitalize on opportunities for further growth and innovation in the
pharmaceutical sector.
The company aims to collect Rs 136 crore through a pre-IPO placement.
With each passing week, the pharmaceutical industry
continues to evolve and innovate, driven by a shared commitment to advancing
healthcare worldwide. Stay tuned to Pharma Delta for your weekly dose of
industry insights and updates. Together, we'll navigate the ever-changing
landscape of healthcare innovation and make strides towards a healthier future.
0 Comments